Abstract
Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis.
John C Mavropoulos, Miguel Cuchacovich, Carolina Llanos, Juan C Aguillón, Hector Gatica, Salvatore V Pizzo and Mario Gonzalez-Gronow
The Journal of Rheumatology November 2005, 32 (11) 2116-2124;
John C Mavropoulos
Miguel Cuchacovich
Carolina Llanos
Juan C Aguillón
Hector Gatica
Salvatore V Pizzo
In this issue
The Journal of Rheumatology
Vol. 32, Issue 11
1 Nov 2005
Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis.
John C Mavropoulos, Miguel Cuchacovich, Carolina Llanos, Juan C Aguillón, Hector Gatica, Salvatore V Pizzo, Mario Gonzalez-Gronow
The Journal of Rheumatology Nov 2005, 32 (11) 2116-2124;
Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis.
John C Mavropoulos, Miguel Cuchacovich, Carolina Llanos, Juan C Aguillón, Hector Gatica, Salvatore V Pizzo, Mario Gonzalez-Gronow
The Journal of Rheumatology Nov 2005, 32 (11) 2116-2124;